My SciELO
Custom servicesServices on Demand
Journal
Article
Spanish (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Cited by Google 
Similars in
SciELO 
Similars in Google
Share
Permalink
Ars Pharmaceutica (Internet)
On-line version ISSN 2340-9894
Abstract
GOODARZI, Rezvan et al. Estudio comparativo de las actividades in vitro de productos comerciales de polimixina B sobre Pseudomonas aeruginosa aislada de pacientes hospitalizados. Ars Pharm [online]. 2021, vol.62, n.3, pp.270-279. Epub Sep 27, 2021. ISSN 2340-9894. https://dx.doi.org/10.30827/ars.v62i3.17851.
Introduction:
Polymyxin B has been applied as one of the last-resort antibiotics for the treatment of multidrug resistance among Gram-negative bacterial infections. Due to side effects such as renal toxicity, the use of polymyxin is associated with limitations. The present study evaluates in vitro antibacterial activity of a number of polymyxin B commercial products against Pseudomonas aeruginosa.
Methods:
This study included 63 non-duplicated P. aeruginosa isolates examined for in vitro polymyxin B susceptibility testing using the following powder disks: polymyxin B sulfate, otosporin, Poly-Mxb, and Myxacort. MIC50 and MIC90 have also been identified for polymyxin B antibiotics.
Results:
Myxacort had functional activity against most P. aeruginosa isolates, and only seven isolates had a relatively high MIC. The activities of Poly-MXb and Myxacort were the same as otosporin.
Conclusions:
Our findings revealed that the national generic polymyxin B product (Myxacort), and two external products (Otosporin, Poly-MXb) are similar in terms of microbiological activity.
Keywords : Pseudomonas aeruginosa; Polymyxin B products; Broth microdilution method.
